Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program

Keyphrases

• Graft-versus-host Disease (GvHD) 100%
• Expanded Access 100%
• Safety Analysis 100%
• Ruxolitinib 100%
• Steroid-refractory 100%
• Serious Adverse Events 40%
• Steroid-refractory Graft-versus-host Disease 30%
• Sepsis 20%
• Disease Groups 20%
• Pneumonia 10%
• Respiratory Failure 10%
• Clinical Trials 10%
• Hematological Malignancies 10%
• Twice Daily 10%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 10%
• Data Extraction 10%
• Starting Dose 10%
• Tolerability 10%
• 12-year-olds 10%
• Janus Kinase 1 (JAK1) 10%
• Lung Infection 10%
• JAK2 Inhibitor 10%
• Chronic Steroids 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Graft Versus Host Disease 100%
• Ruxolitinib 100%
• Adverse Event 57%
• Acute Graft Versus Host Disease 42%
• Graft Versus Host Reaction 42%
• Sepsis 28%
• Infection 14%
• Respiratory Failure 14%
• Clinical Trial 14%
• Hematologic Malignancy 14%
• Tolerability 14%
• Lung Infection 14%
• Janus Kinase 2 Inhibitor 14%
• Janus Kinase 1 14%

Immunology and Microbiology

• Chronic Graft Versus Host Disease 100%
• Graft-Versus-Host Disease 42%
• Acute Graft Versus Host Disease 42%
• Hematopoietic Cell 14%
• Cell Transplantation 14%
• Data Extraction 14%